A small clinical trial with a pharmacokinetic sub-study, led by a world-renowned pharmacologist at the University of Houston, has demonstrated the promising effectiveness of the drug Riluzole for improving functionality in people with acute spinal cord injuries (SCI) if the drug is taken within 12 hours post-injury.
Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020 – Psychedelic Alpha
Single and multiple oral doses of GM-1020, a novel non-competitive NMDA channel blocker, were well-tolerated with no serious or severe adverse events observed and confirmed